MK2i improves alkali burn clinical signs.
(A) Representative slit lamp images showing differences between the 4 different groups in corneal edema, NV and fluorescein staining on day 7 after alkali burn; (B) Time dependent changes in inflammatory index among the 4 groups on days 4 and 7; (C) Time dependent changes in corneal NV area among the 4 groups on days 4 and 7; (D) Time dependent changes in fluorescein staining among the 4 groups on days 4 and 7. Topical MK2i treatment significantly decreased the corneal inflammatory index. Irrespective of the MK2i dose this inhibitor for the most part decreased clinical signs indicative of a corneal alkali burn. Only fluorescein staining decreased more by day 7 in the 150 μM MK2i treated group. (Data are presented as Mean ± SEM, n = 9. *P < 0.05, **P < 0.01, ***P < 0.001, 15 μM MK2i treated group versus saline treated group; ##P < 0.01, ###P < 0.001, 150 μM MK2i treated group versus saline treated group).